Probiotics in inflammatory bowel disease: is it all gut flora modulation?: Figure 1
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Understanding probiotic action may permit modulation of the immune system, both locally and systemically There is considerable public, media, and scientific interest in “natural” products, including probiotics, in modulating intestinal inflammation and health.1 Intestinal microflora are intimately involved in the generation of immunocompetent cells and tuning the balance between T helper 1 (Th1) and Th2 immunity during the development of the gut associated immune system. It is now generally accepted that the intestinal bacterial flora contributes significantly to the pathogenesis of inflammatory bowel disease (IBD) along with mucosal immune dysregulation and genetic susceptibility. Considerable research is focused on modifying the intestinal flora with probiotic bacteria to attenuate inflammatory activity and prevent relapses in ulcerative colitis, Crohn’s disease, and pouchitis. Although both Lactobacillus species and Bifidobacterium species are frequently used, the optimum use of probiotics in IBD requires greater understanding of their effects on the immune system. A rationale for the use of probiotics in IBD stems from reports of dysbiosis in the intestinal flora in ulcerative colitis, Crohn’s disease, and pouchitis, either by conventional anaerobic culture or by analysis using molecular probes. It is however unclear whether such alterations in intestinal flora drives the inflammation or is a consequence of it. The practical application of probiotic strategy has been especially encouraged by the positive results of a trial in its use for the prevention and treatment of pouchitis.2,3 The multispecies probiotics used pose special challenges in identifying precise mechanism of action, although alterations in faecal flora have been demonstrated.4 Despite some positive trials, generalisation from pouchitis to their use for all forms of IBD appears somewhat premature, however, as for example, a trial of administration of Lactobacillus GG after surgical resection for Crohn’s disease proved ineffective in preventing relapse.5 Further studies are therefore …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168
Pigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417
Nicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., & Vaulont, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151179498 · Cited by 1,233
Severe iron deficiency anemia in transgenic mice expressing liver hepcidin
Nicolas, G., Bennoun, M., Porteu, A., Mativet, S., Beaumont, C., Grandchamp, B., Sirito, M., Sawadogo, M., Kahn, A., & Vaulont, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072632499 · Cited by 880
Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis
Roetto, A., Papanikolaou, G., Politou, M., Alberti, F., Girelli, D., Christakis, J., Loukopoulos, D., & Camaschella, C. (2003) · Nature Genetics · doi:10.1038/ng1053 · Cited by 860
Resta-Lenert, S., & Barrett, K. E. (2003) · Gut · doi:10.1136/gut.52.7.988 · Cited by 642 · cited 3×
“14 Juvenile haemo-chromatosis is genetically heterogeneous with a second form mapping to chromosome 1q21.”
Weinstein, D. A., Roy, C. N., Fleming, M. D., Loda, M. F., Wolfsdorf, J. I., & Andrews, N. C. (2002) · Blood · doi:10.1182/blood-2002-04-1260 · Cited by 632
Hunter, H. N., Fulton, D. B., Ganz, T., & Vogel, H. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205305200 · Cited by 400
Chen, C.-C., Chen, N., & Lau, L. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008087200 · Cited by 305
Cited by
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457
Calcinaro, F., Dionisi, S., Marinaro, M., Candeloro, P., Bonato, V., Marzotti, S., Corneli, R. B., Ferretti, E., Gulino, A., Grasso, F., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1831-2 · Cited by 352
Interactions between Intestinal Microbiota and Host Immune Response in Inflammatory Bowel Disease
Zhang, M., Sun, K., Wu, Y., Yang, Y., Tso, P., & Wu, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00942 · Cited by 347
“Further studies on the efficacy, safety, and underlying mechanisms of action are required before probiotics may be recommended for the treatment of IBD patients (188).”
BackgroundProbiotic Prophylaxis of Ventilator-associated Pneumonia: A Blinded, Randomized, Controlled Trial
Morrow, L. E., Kollef, M. H., & Casale, T. B. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1853oc · Cited by 346
Microbes, immunoregulation, and the gut: Figure 1
Rook, G. A. W., & Brunet, L. R. (2005) · Gut · doi:10.1136/gut.2004.053785 · Cited by 334
Metadata
- Authors
- Ghosh, S., van Heel, D., & Playford, R. J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2004-04-13
- Volume
- 53
- Issue
- 5
- Pages
- 620-622
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2047511413
- Cited by
- 105
- References
- 11
- FWCI
- 14.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.